Can Alpha-1 PiMZ Carriers Get COPD If They Don't Smoke?
Published: | Updated:
Lifelong non-smokers with the Alpha-1 PiMZ genotype are highly unlikely to develop severe COPD from carrier status alone. However, PiMZ carriers do face liver risks and should avoid lung irritants, limit alcohol, and get clinical testing to confirm at-home DNA results.
Key Takeaways
- • Lifelong non-smokers with the PiMZ genotype rarely develop severe COPD from their Alpha-1 carrier status alone.
- • At-home genetic tests should always be clinically confirmed with a blood test to verify gene type and measure actual protein levels.
- • PiMZ carriers face an increased risk of progressive liver disease due to abnormally folded proteins getting trapped in the liver.
- • Maintaining a healthy weight and strictly moderating alcohol intake are critical to protecting liver function for carriers.
- • Newly identified carriers should establish baseline health metrics through spirometry testing and liver enzyme blood work.
Finding out you are a PiMZ carrier for Alpha-1 antitrypsin deficiency—especially if you discovered it through an at-home genetic test—can be alarming. However, if you are a lifelong non-smoker, the short answer is reassuring: it is highly unlikely that you will develop severe COPD from your PiMZ status alone [1][2]. While your risk is slightly higher than someone without the genetic variant, remaining smoke-free is the most powerful way to protect your lungs [3].
First Step: Confirm Your At-Home Test
Direct-to-consumer DNA tests (like 23andMe) are a helpful starting point, but they only check for the most common genetic variants. It is possible for these tests to miss rare but serious variants (such as a “Null” gene). If you have one “Z” gene and one “Null” gene, an at-home test might mistakenly tell you that you are a PiMZ carrier when you actually have a more severe deficiency.
Because of this, you should share your results with your doctor and ask for a clinical blood test. This simple blood draw will check your precise genetic type and measure the actual level of Alpha-1 protein in your blood to confirm your true status.
What Does Being a PiMZ Carrier Mean?
Alpha-1 antitrypsin (AAT) is a protein produced by your liver that travels to your lungs to protect them from inflammation. Your genes provide the instructions for making this protein. A “PiMM” result means you have two normal genes. As a PiMZ carrier, you inherited one normal “M” gene and one abnormal “Z” gene.
Because you still have one fully functioning “M” gene, your body typically produces about 40% to 60% of the normal amount of AAT protein [4]. In the medical community, there is a recognized “protective threshold” for this protein—an amount needed in the blood to adequately defend the lungs. This threshold is generally considered to be 11 micromol/L (or roughly 57 mg/dL) [5][6]. The vast majority of PiMZ carriers naturally produce levels above this protective threshold [4]. This is why, without the extreme stress of cigarette smoke, your lungs usually have enough protection to prevent severe chronic obstructive pulmonary disease (COPD) or emphysema.
Environmental Risks for Non-Smokers
While you have enough protein for normal daily life, your lungs have less reserve to handle heavy stress compared to someone with a PiMM genotype. Think of it like having a good savings account, but not a massive one—you can handle everyday expenses, but you want to avoid unnecessary financial shocks.
Even if you have never smoked, you should be vigilant about avoiding other lung irritants, as chronic exposure to pollutants can modify your lung health [3][7]. You should actively minimize exposure to:
- Secondhand smoke and vaping aerosols [3][8]
- Occupational hazards like chemical fumes, silica, or heavy dust [3][8]
- Indoor air pollution such as fumes from poorly ventilated wood-burning stoves
- Heavy outdoor air pollution (try to limit outdoor exercise on high-smog days)
Protecting your lungs with vaccines: Since your lungs are more vulnerable to severe infections, it is highly recommended to stay up-to-date on vaccines that prevent respiratory illnesses, including the annual flu shot, COVID-19 vaccines, and pneumonia (pneumococcal) vaccines.
The Liver Connection: A Different Type of Risk
Many people focus purely on their lungs when researching Alpha-1, but for PiMZ carriers, the liver is equally important. The abnormal “Z” protein produced by your body has a misshapen structure. Instead of easily moving out of the liver and into the bloodstream, some of this mutant protein can misfold and get stuck inside your liver cells [9][10][11].
Doctors refer to this as a toxic gain of function—the trapped protein can cause irritation and inflammation in the liver over time [9][10]. While routine, intensive liver screening isn’t typically recommended for asymptomatic PiMZ carriers, you do have an increased risk for developing progressive liver disease compared to the general public [12][13].
This risk is heavily influenced by how well you treat your liver. Your liver can usually handle the trapped “Z” protein if it isn’t facing other stressors. However, the risk of liver disease multiplies if you add other burdens [14][15]. To protect your liver, it is critical to:
- Be highly cautious with alcohol: While you do not necessarily need to be 100% sober if your liver is currently healthy, alcohol forces the liver to work harder and adds significant stress. Standard guidelines advise strict moderation, and if you ever develop signs of liver damage, complete abstinence is required.
- Maintain a healthy weight: Metabolic dysfunction and fatty liver disease (MASLD) interact dangerously with the PiMZ variant, significantly increasing the risk of scarring (fibrosis) and cirrhosis [14][15].
- Get Hepatitis vaccines: Ask your doctor about getting vaccinated against Hepatitis A and B to prevent viral liver infections.
Establishing Baseline Care and Next Steps
You do not need to panic, but you should use this genetic discovery to establish proactive care with your primary care doctor. At your next physical, ask to establish a baseline for your lung and liver health. This typically involves a simple breathing test (spirometry) to check your lung function, and a routine blood test (checking AST and ALT enzymes) to assess your liver health [16][17].
Family Planning and Testing: Because you are a carrier, standard medical guidelines recommend “cascade family screening” [18][19]. This means informing your parents and siblings so they can discuss testing with their doctors. For your children, medical professionals generally recommend waiting until they are adults (who can consent to their own genetic testing) to check their carrier status, unless they are experiencing unexplained liver or lung symptoms.
Frequently Asked Questions
Do Alpha-1 PiMZ carriers usually get COPD if they never smoke?
Are at-home genetic tests like 23andMe fully accurate for Alpha-1?
Does being a PiMZ carrier affect the liver?
What tests do I need to check my lung and liver health as a PiMZ carrier?
How can I protect my lungs and liver as an Alpha-1 carrier?
Questions for Your Doctor
- • Can we order a clinical blood test to measure my actual Alpha-1 antitrypsin protein levels and officially confirm my at-home genetic test results?
- • Should we schedule a baseline spirometry test to establish my current lung function?
- • Can we run a blood test to check my baseline AST and ALT liver enzymes?
- • Given my PiMZ status, what are your specific recommendations for my personal alcohol consumption?
- • Am I currently up-to-date on all recommended respiratory and liver vaccines, including pneumonia and Hepatitis A/B?
Questions for You
- • Have I been routinely exposed to any lung irritants at my workplace or in my home, such as chemical fumes, heavy dust, or secondhand smoke?
- • How would I honestly describe my current relationship with alcohol, and are there straightforward ways I can reduce my intake to protect my liver?
- • Am I experiencing any unexplained respiratory symptoms, such as getting unusually winded during activities I used to find easy?
- • Have any of my blood relatives been diagnosed with early-onset lung disease, unexplained liver cirrhosis, or COPD?
Want personalized information?
Type your question below to get evidence-based answers tailored to your situation.
References
- 1
Alpha-1 Antitrypsin PiMZ Genotype Is Associated with Chronic Obstructive Pulmonary Disease in Two Racial Groups.
Foreman MG, Wilson C, DeMeo DL, et al.
Annals of the American Thoracic Society 2017; (14(8)):1280-1287 doi:10.1513/AnnalsATS.201611-838OC.
PMID: 28380308 - 2
Alpha-1 Antitrypsin MZ Heterozygosity Is an Endotype of Chronic Obstructive Pulmonary Disease.
Ghosh AJ, Hobbs BD, Moll M, et al.
American journal of respiratory and critical care medicine 2022; (205(3)):313-323 doi:10.1164/rccm.202106-1404OC.
PMID: 34762809 - 3
Alpha-1 Antitrypsin Replacement in Patients With COPD.
Wells AD, Woods A, Hilleman DE, Malesker MA
P & T : a peer-reviewed journal for formulary management 2019; (44(7)):412-415.
PMID: 31258312 - 4
Optimal alpha-1 antitrypsin level cutoffs for genotype identification in patients with chronic liver disease.
Prakash S, Murali AR
Hepatology communications 2023; (7(2)):e0023 doi:10.1097/HC9.0000000000000023.
PMID: 37133851 - 5
Exogenous alpha 1-antitrypsin down-regulates SERPINA1 expression.
Karadagi A, Johansson H, Zemack H, et al.
PloS one 2017; (12(5)):e0177279 doi:10.1371/journal.pone.0177279.
PMID: 28486562 - 6
[Alpha 1-antitrypsin deficiency].
Mornex JF
Revue des maladies respiratoires 2022; (39(8)):698-707 doi:10.1016/j.rmr.2022.02.062.
PMID: 35715315 - 7
[Alpha-1 antitrypsin deficiency: A model of alteration of protein homeostasis or proteostasis].
Vignaud H, Cullin C, Bouchecareilh M
Revue des maladies respiratoires 2015; (32(10)):1059-71.
PMID: 26386628 - 8
The Effects of Rare SERPINA1 Variants on Lung Function and Emphysema in SPIROMICS.
Ortega VE, Li X, O'Neal WK, et al.
American journal of respiratory and critical care medicine 2020; (201(5)):540-554 doi:10.1164/rccm.201904-0769OC.
PMID: 31661293 - 9
Systematic review: the natural history of alpha-1 antitrypsin deficiency, and associated liver disease.
Townsend SA, Edgar RG, Ellis PR, et al.
Alimentary pharmacology & therapeutics 2018; (47(7)):877-885 doi:10.1111/apt.14537.
PMID: 29446109 - 10
Clinical and histologic features of adults with alpha-1 antitrypsin deficiency in a non-cirrhotic cohort.
Clark VC, Marek G, Liu C, et al.
Journal of hepatology 2018; (69(6)):1357-1364 doi:10.1016/j.jhep.2018.08.005.
PMID: 30138687 - 11
Alpha-1-Antitrypsin Deficiency Liver Disease.
Patel D, Teckman JH
Clinics in liver disease 2018; (22(4)):643-655 doi:10.1016/j.cld.2018.06.010.
PMID: 30266154 - 12
Alpha-1 antitrypsin Pi∗Z allele is an independent risk factor for liver transplantation and death in patients with advanced chronic liver disease.
Balcar L, Scheiner B, Urheu M, et al.
JHEP reports : innovation in hepatology 2022; (4(11)):100562 doi:10.1016/j.jhepr.2022.100562.
PMID: 36176936 - 13
Review article: New developments in biomarkers and clinical drug development in alpha-1 antitrypsin deficiency-related liver disease.
Loomba R, Clark G, Teckman J, et al.
Alimentary pharmacology & therapeutics 2024; (59(10)):1183-1195 doi:10.1111/apt.17967.
PMID: 38516814 - 14
Genetic drivers of liver cirrhosis: The role of SERPINA1 and PNPLA3 variants in disease onset and progression.
Holinka M, Frankova S, Adamcova Selcanova S, et al.
PloS one 2025; (20(9)):e0333051 doi:10.1371/journal.pone.0333051.
PMID: 41004464 - 15
Both α-1-antitrypsin Z phenotypes and low caeruloplasmin levels are over-represented in alcohol and nonalcoholic fatty liver disease cirrhotic patients undergoing liver transplant in Ireland.
El-Rayah EA, Twomey PJ, Wallace EM, McCormick PA
European journal of gastroenterology & hepatology 2018; (30(4)):364-367 doi:10.1097/MEG.0000000000001056.
PMID: 29324588 - 16
Alpha-1 antitrypsin deficiency is under-recognized in individuals with cirrhosis undergoing liver transplantation.
Shah RS, Alsuleiman B, Bena J, et al.
European journal of gastroenterology & hepatology 2021; (33(1S Suppl 1)):e233-e238 doi:10.1097/MEG.0000000000002005.
PMID: 33252420 - 17
Alpha-1 antitrypsin deficiency-associated liver disease: From understudied disorder to the poster child of genetic medicine.
Fromme M, Klebingat F, Ellis P, Strnad P
Hepatology communications 2025; (9(5)) doi:10.1097/HC9.0000000000000699.
PMID: 40227077 - 18
Variants of SERPINA1 and the increasing complexity of testing for alpha-1 antitrypsin deficiency.
Foil KE
Therapeutic advances in chronic disease 2021; (12_suppl()):20406223211015954 doi:10.1177/20406223211015954.
PMID: 34408833 - 19
Alpha-1 Antitrypsin Deficiency: Principles of Care.
Rodrigues JF, Mineiro A, Reis A, et al.
Acta medica portuguesa 2020; (33(6)):433-439 doi:10.20344/amp.12950.
PMID: 32504520
This page provides educational information about Alpha-1 PiMZ carrier risks and lifestyle management. It does not replace professional medical advice. Always consult your healthcare provider to confirm genetic test results and establish a personalized care plan.
Stay up to date
Get notified when new research about Alpha-1-antitrypsin deficiency is published.
No spam. Unsubscribe anytime.